Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiten Vora

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Medical Economics|November 26, 2014
A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UKIskandar Idris, Jason Gordon, Carl Tilling, et al.
Diabetes, Obesity & Metabolism|April 15, 2020
Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?Francesco Giorgino, Jiten Vora, Peter Fenici, et al.
Cardiovascular Diabetology|November 23, 2020
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal riskFrancesco Giorgino, Jiten Vora, Peter Fenici, et al.
European Journal of Endocrinology|January 27, 2018
MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?Russell L Esterline, Allan Vaag, Jan Oscarsson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 2, 2014
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trialsJiten Vora, Torsten Christensen, Azhar Rana, et al.
Clinical Drug Investigation|February 20, 2016
Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given AloneTina Vilsbøll, Jiten Vora, Henrik Jarlov, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 9, 2013
Evaluation of insulin use and value for money in type 2 diabetes in the United kingdomJason Gordon, Marc Evans, Phil McEwan, et al.
Journal of the American Geriatrics Society|August 14, 2012
Insulin use in elderly adults: risk of hypoglycemia and strategies for careRobert J Ligthelm, Marcel Kaiser, Jiten Vora, et al.
BMC Endocrine Disorders|July 23, 2014
Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational studyTaner Damci, Rifat Emral, Anne Louise Svendsen, et al.
Diabetes, Obesity & Metabolism|September 2, 2017
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetesRobert Ritzel, Ronan Roussel, Andrea Giaccari, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Medical Economics|November 26, 2014
A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UKIskandar Idris, Jason Gordon, Carl Tilling, et al.
Diabetes, Obesity & Metabolism|April 15, 2020
Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?Francesco Giorgino, Jiten Vora, Peter Fenici, et al.
Cardiovascular Diabetology|November 23, 2020
Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal riskFrancesco Giorgino, Jiten Vora, Peter Fenici, et al.
European Journal of Endocrinology|January 27, 2018
MECHANISMS IN ENDOCRINOLOGY: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?Russell L Esterline, Allan Vaag, Jan Oscarsson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|August 2, 2014
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trialsJiten Vora, Torsten Christensen, Azhar Rana, et al.
Clinical Drug Investigation|February 20, 2016
Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given AloneTina Vilsbøll, Jiten Vora, Henrik Jarlov, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|January 9, 2013
Evaluation of insulin use and value for money in type 2 diabetes in the United kingdomJason Gordon, Marc Evans, Phil McEwan, et al.
Journal of the American Geriatrics Society|August 14, 2012
Insulin use in elderly adults: risk of hypoglycemia and strategies for careRobert J Ligthelm, Marcel Kaiser, Jiten Vora, et al.
BMC Endocrine Disorders|July 23, 2014
Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational studyTaner Damci, Rifat Emral, Anne Louise Svendsen, et al.
Diabetes, Obesity & Metabolism|September 2, 2017
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetesRobert Ritzel, Ronan Roussel, Andrea Giaccari, et al.
Pageof 5